Caplin Point Laboratories
Market Cap
₹30.6b
Last Updated
2019/10/17 12:38 UTC
Data Sources
Company Financials +
Executive Summary
Caplin Point Laboratories Limited produces, develops, markets, and exports generic formulations and branded products in India and internationally.
Snowflake
Fundamentals
Flawless balance sheet with proven track record.
Similar Companies
Share Price & News
How has Caplin Point Laboratories's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-2.5%
524742
3.0%
IN Pharmaceuticals
3.1%
IN Market
1 Year Return
-7.4%
524742
-18.9%
IN Pharmaceuticals
3.7%
IN Market
Return vs Industry: 524742 exceeded the Indian Pharmaceuticals industry which returned -18.9% over the past year.
Return vs Market: 524742 underperformed the Indian Market which returned 3.7% over the past year.
Shareholder returns
| 524742 | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.5% | 3.0% | 3.1% |
| 30 Day | -6.5% | -4.2% | 5.7% |
| 90 Day | -5.8% | -2.5% | 1.4% |
| 1 Year | -6.9%-7.4% | -18.2%-18.9% | 5.9%3.7% |
| 3 Year | 13.6%12.3% | -26.1%-27.6% | 22.3%16.0% |
| 5 Year | 373.9%359.7% | -11.7%-14.3% | 42.5%28.9% |
Price Volatility Vs. Market
How volatile is Caplin Point Laboratories's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Caplin Point Laboratories undervalued compared to its fair value and its price relative to the market?
15.76x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Undervalued: 524742 (₹394.6) is trading above our estimate of fair value (₹66.22)
Significantly Undervalued: 524742 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 524742 is poor value based on its PE Ratio (15.8x) compared to the Pharmaceuticals industry average (15.8x).
PE vs Market: 524742 is poor value based on its PE Ratio (15.8x) compared to the Indian market (13.2x).
Price to Earnings Growth Ratio
Low PEG Ratio: Insufficient data to calculate 524742's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 524742 is overvalued based on its PB Ratio (5x) compared to the IN Pharmaceuticals industry average (1.5x).
Next Steps
Future Growth
How is Caplin Point Laboratories forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
-0.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 524742's earnings are forecast to decline over the next 3 years (-0.4% per year).
Earnings vs Market: 524742's earnings are forecast to decline over the next 3 years (-0.4% per year).
High Growth Earnings: 524742's earnings are forecast to decline over the next 3 years.
Revenue vs Market: 524742's revenue (13.2% per year) is forecast to grow faster than the Indian market (11.4% per year).
High Growth Revenue: 524742's revenue (13.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: Insufficient data to determine if 524742's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Caplin Point Laboratories performed over the past 5 years?
36.4%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: 524742's earnings have grown significantly by 36.4% per year over the past 5 years.
Accelerating Growth: 524742's earnings growth over the past year (29.8%) is below its 5-year average (36.4% per year).
Earnings vs Industry: 524742 earnings growth over the past year (29.8%) exceeded the Pharmaceuticals industry 14.4%.
Return on Equity
High ROE: 524742's Return on Equity (29.9%) is considered high.
Return on Assets
ROA vs Industry: 524742 has a higher Return on Assets than the Pharmaceuticals industry average last year.
Return on Capital Employed
ROCE Improving: 524742's Return on Capital Employed has declined over the past 3 years.
Next Steps
Financial Health
How is Caplin Point Laboratories's financial position?
Financial Position Analysis
Short Term Liabilities: 524742's short term assets (₹4.9B) exceeds its short term liabilities (₹861.1M)
Long Term Liabilities: 524742's short term assets (4.9B) exceeds its long term liabilities (234.2M)
Debt to Equity History and Analysis
Debt Level: 524742's debt to equity ratio (0.05%) is considered satisfactory
Reducing Debt: 524742's debt to equity ratio has reduced from 5.4% to 0.05% over the past 5 years.
Debt Coverage: 524742's debt is well covered by operating cash flow (29088.2%).
Interest Coverage: 524742's interest payments on its debt are well covered by EBIT (3811.9x coverage).
Balance Sheet
Inventory Level: 524742 has a high level of physical assets or inventory.
Debt Coverage by Assets: 524742's debt is covered by short term assets (assets are 1721.367500x debt).
Next Steps
Dividend
What is Caplin Point Laboratories's current dividend yield, its reliability and sustainability?
0.56%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: 524742's dividend (0.56%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.6%).
High Dividend: 524742's dividend (0.56%) is low compared to the top 25% of dividend payers in the Indian market (2.48%).
Stable Dividend: Whilst dividend payments have been stable, 524742 has been paying a dividend for less than 10 years.
Growing Dividend: 524742's dividend payments have increased, but the company has only paid a dividend for 9 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (8.8%), 524742's dividend payments are thoroughly covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
What is the CEO of Caplin Point Laboratories's salary, the management and board of directors tenure and is there insider trading?
4.6yrs
Average management tenure
CEO
Sridhar Ganesan (64yo)
4.6yrs
Tenure
₹5,690,000
Compensation
Dr. Sridhar Ganesan has been the Managing Director of Caplin Point Laboratories Ltd since March 28, 2015. Dr. Ganesan has been Whole Time Director of Caplin Point Laboratories Ltd since August 25, 2014. Dr ...
CEO Compensation Analysis
Compensation vs. Market: Sridhar's total compensation ($USD79.68K) is about average for companies of similar size in the Indian market ($USD317.97K).
Compensation vs Earnings: Sridhar's compensation has been consistent with company performance over the past year.
Management Age and Tenure
4.6yrs
Average Tenure
Experienced Management: 524742's management team is considered experienced (4.6 years average tenure).
Board Age and Tenure
5.3yrs
Average Tenure
67yo
Average Age
Experienced Board: 524742's board of directors are considered experienced (5.3 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chairman of the Board Non-Executive Chairman |
| Shares | 10,000 |
| Max Price | ₹331.40 |
Ownership Breakdown
Management Team
Partheeban Siddarth
Chief Operating Officer
- Tenure: 8.2yrs
- Compensation: ₹1.82m
V. Natarajan
Head of Formulation & Development -Injectibles
- Tenure: 0yrs
Sridhar Ganesan (64yo)
MD & Whole Time Director
- Tenure: 4.6yrs
- Compensation: ₹5.69m
S. Kumar
Company Secretary & Compliance Officer
- Tenure: 0yrs
- Compensation: ₹794.00k
D. Muralidharan
Chief Financial Officer
- Tenure: 3.7yrs
- Compensation: ₹2.65m
Board Members
V. Thirumalai (78yo)
Non-Executive Independent Director
- Tenure: 25.3yrs
- Compensation: ₹200.00k
D. Mishra (64yo)
Non-Executive Non-Independent Director
- Tenure: 11.8yrs
- Compensation: ₹80.00k
C. Paarthipan (67yo)
Non-Executive Chairman
- Tenure: 0yrs
R. Ravichandran (62yo)
Non-Executive Independent Director
- Tenure: 5.4yrs
- Compensation: ₹300.00k
Sridhar Ganesan (64yo)
MD & Whole Time Director
- Tenure: 4.6yrs
- Compensation: ₹5.69m
K. John (67yo)
Non-Executive Independent Director
- Tenure: 5.2yrs
- Compensation: ₹200.00k
R. Viswanathan (67yo)
Non-Executive Independent Director
- Tenure: 4.4yrs
- Compensation: ₹100.00k
K. Prasad (71yo)
Non-Executive Independent Director
- Tenure: 4.7yrs
- Compensation: ₹260.00k
D. Sathyanarayanan (60yo)
Non-Executive Independent Director
- Tenure: 2.9yrs
- Compensation: ₹220.00k
Company Information
Caplin Point Laboratories Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Caplin Point Laboratories Limited
- Ticker: 524742
- Exchange: BSE
- Founded: 1990
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹30.594b
- Shares outstanding: 75.64m
- Website: https://www.caplinpoint.net
Location
- Caplin Point Laboratories Limited
- NARBHAVI
- No. 3, Lakshmanan Street
- Chennai
- Tamil Nadu
- 600017
- India
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 524742 | BSE (Mumbai Stock Exchange) | Yes | Equity Shares | IN | INR | Feb 2002 |
| CAPPL | NSEI (National Stock Exchange of India) | Yes | Equity Shares | IN | INR | Feb 2002 |
Biography
Caplin Point Laboratories Limited produces, develops, markets, and exports generic formulations and branded products in India and internationally. It provides liquid injections, lyophilised injections, opt ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/17 12:38 |
| End of Day Share Price | 2019/10/17 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2019/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.